Newsfeeds Archive - Spark Newswire

3 minute read

Vistagen Announces Results From Phase 2A Pilot Study Of PH15 For Improvement Of Psychomotor Impairment Caused By Mental Fatigue

April 25, 8:40 AM

PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participantsPH15 was safe and well-tolerated with an adverse

VTGN

2 minute read

Vistagen Initiates PALISADE-3 Phase 3 Study Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder Following Results Of PALISADE-2

By Benzinga Newsdesk

April 1, 8:31 AM

Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorderSocial anxiety disorder affects over 25 million AmericansVistagen (NASDAQ:VTGN), a late clinical-stage

VTGN

5 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

February 19, 1:35 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…

ARQT

8 minute read

Earnings

Earnings Scheduled For February 13, 2024

By Benzinga Insights

February 13, 6:05 AM

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.

ABNB

1 minute read

Earnings

VistaGen Therapeutics’s Earnings: A Preview

By Benzinga Insights

February 12, 3:01 PM

VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Tuesday, 2024-02-13. Here’s what investors…

VTGN

3 minute read

Vistagen Receives Notice From European Patent Office Of Intention To Grant Patent For AV-101 To Treat Neuropathic Pain

By Benzinga Newsdesk

December 27, 9:30 AM

Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demonstrate AV-101's robust effects similar to gabapentin but with a better side effect

VTGN

1 minute read

Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment

By Vandana Singh

December 4, 3:39 PM

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other

VTGN

1 minute read

Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst

By Vandana Singh

November 14, 3:08 PM

Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder (SAD).

VTGN

22 minute read

Earnings

Earnings Scheduled For November 9, 2023

By Benzinga Insights

November 9, 7:52 AM

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.

AAOI

1 minute read

Earnings

VistaGen Therapeutics Earnings Preview

By Benzinga Insights

November 8, 3:01 PM

VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Thursday, 2023-11-09. Here’s what investors…

VTGN